In endometrioid carcinomas, the ratios of genomic alterations in TP53, PIK3CA, KRAS ARID1A, PTEN, and CTNNB1 were 55.4%, 43.5%, 31.5%, 29.3%, 27.2%, and 19.6%, respectively. This evidence concerns the gene TP53 and endometrioid adenocarcinoma.